MedCity News February 2, 2025
As the pharmaceutical landscape evolves, small-molecule CDMOs will be essential in balancing supply and demand, driving innovation, and improving patient outcomes. They must continue embracing innovation and strategic agility to survive and thrive in this complex environment.
While large-molecule therapeutics capture most headlines, small-molecule drugs face significant challenges, struggling with funding cuts, supply chain disruptions, and growing demand. At the same time, the small molecule market is projected to grow significantly over the next decade, fueled by a renewed focus on patient-centric drug discovery and innovation in areas like oncology, cardiology, and neurology.
The small molecule drug discovery market is on track to grow to $106 billion by 2031, up from $57.41 billion in 2023. This growth highlights the...
Today's Sponsors
Today's Sponsor